

## 2017 OPA Annual Conference Learning Objectives

### **ACPE #0129-0000-17-015-L04-P**

#### **Impaired Pharmacists and the Board of Pharmacy Hearings Process**

*Jarrold Grossman, R.Ph., PharmD; Nick Kallis, R.Ph.; Gary Rutherford, R.Ph.; Joseph Sabino, R.Ph., MS, Pharmacists Rehabilitation Organization*

At the completion of this activity, the participant will be able to:

1. identify the sections of the Ohio Revised Code and Ohio Administrative Code governing Chapter 119 proceedings;
2. identify and apply the necessary facts needed to render an appropriate decision to a case of an impaired pharmacist;
3. identify and apply the appropriate laws to a case of an impaired pharmacist; and
4. discuss the human components of the decisions made about impaired pharmacists and pharmacy interns.

### **ACPE #0129-0000-17-016-L04-P**

#### **Hot Topics for Ohio Pharmacists**

*Jennifer L. Rodis, PharmD, BCPS, Assistant Dean for Outreach and Engagement, OSU College of Pharmacy; Brigid Groves, PharmD, MS, Clinical Coordinator, Kroger; Brianna Porter, PharmD, MS Community Practice Advancement Fellow; Dana Bachmann, PharmD, MS Community Practice Administration Resident; and Bella Mehta, PharmD, FAPhA, Professor of Clinical Pharmacy, OSU College of Pharmacy*

At the completion of this activity, the participant will be able to:

1. review Ohio's progress in pharmacy practice advancement over recent years;
2. discuss hot topics in pharmacy practice; and
3. recognize the Ohio pharmacist's role in continuing to advance the profession of pharmacy at the local, state, and national level.

### **ACPE #0129-0000-17-017-L01-P**

#### **Not Waving, but Drowning: Detecting and Treating Major Depressive Disorder**

*Chris Paxos, PharmD, BCPP, BCPS, CGP, Pharmacotherapy Specialist, Psychiatry, Cleveland Clinic Akron General; Associate Professor, Pharmacy Practice, NEOMED*

At the completion of this activity, the participant will be able to:

1. discuss the DSM-5 diagnostic criteria for major depressive disorder;
2. identify depression screening tools that can be used in ambulatory care and community pharmacy settings;
3. propose methods for incorporating depression screening into ambulatory care and community pharmacy settings;
4. describe the approach for treating major depressive disorder with pharmacotherapy; and
5. compare and contrast pharmacologic properties of modern antidepressants.

### **ACPE #0129-0000-17-018-L04-P**

#### **Preceptor Development: Pushing Students to Become Active Participants in Patient Care**

*Experiential Directors from Ohio's Colleges/Schools of Pharmacy: Tonya Dauterman and Tim Burkart, UF; Thad Franz, Cedarville; Donnie Sullivan and Julie Legg, OSU; Jennie Grundey, ONU*

At the completion of this activity, the participant will be able to:

1. define interprofessional experiences/education (IPE);
2. identify learner to learner opportunities for your students;
3. identify learner to practitioner opportunities for your students;
4. review the Pharmacist Patient Care Process (PPCP);
5. identify how IPE and the PPCP activities can be implemented on your rotation;
6. explain how to provide student feedback and evaluate students in their IPE role; and
7. use feedback obtained externally from other health care providers and share with students.

### **ACPE #0129-0000-17-019-L01-P**

#### **Neurobiology of the Substance Use Disorders**

*Jon E. Sprague, R.Ph., PhD, Director & BCI Eminent Scholar  
The Ohio Attorney General's Center for the Future of Forensic Science  
Bowling Green State University*

At the completion of this activity, the participant will be able to:

1. discuss the differences between euphoria, dysphoria, addiction and substance use disorder;
2. recognize the DSM-5 criteria for substance use disorders;
3. identify based on pharmacological mechanism how individual classes of drugs regulate dopamine release in the nucleus accumbens;
4. discuss the cellular mechanisms that result in addiction-induced brain disease; and
5. identify the stages of addiction.

**ACPE #0129-0000-17-020-L01-P**

**2017 OTC and Self-Care Challenge**

*Brigid Groves, R.Ph., PharmD, MS, Clinical Coordinator, Kroger; Justin Brown, R.Ph., PharmD, Staff Pharmacist, WalMart*

At the completion of this activity, the participant will be able to:

1. discuss current topics related to nonprescription medications;
2. describe appropriate nonprescription treatment options for common self-care conditions;
3. identify the rationale for the selection of a particular product for a described self-care condition;
4. describe at least two interactions between over-the-counter and prescription medications; and
5. identify key counseling points for OTC medications.

**ACPE #0129-0000-17-021-L01-P**

**Cardiovascular Pharmacological Pearls**

*Vincent F. Mauro, R.Ph., PharmD, FCCP, Professor of Clinical Pharmacy, The University of Toledo College of Pharmacy and Pharmaceutical Sciences*

At the completion of this activity, the participant will be able to:

1. identify clinically important drug interactions and discuss how to manage them;
2. indicate inappropriate dosing and/or ineffective uses of medications and discuss how to correct them; and
3. recognize clinically important adverse effects and discuss how to address them

**ACPE #0129-0000-17-022-L04-P**

**Elevating the Scope of Pharmacy Practice through a Clinical Privileging Program**

*Robert Weber, PharmD, MS, BCPS, FASHP and Trisha Jordan, PharmD, MS  
OSU Wexner Medical Center and College of Pharmacy*

At the completion of this activity, the participant will be able to:

1. describe changes to Ohio's Consult Agreement Law;
2. highlight opportunities for institutional practice;
3. explain how OSUWMC has implemented consult agreements; and
4. examine OSUWMC's practice model and review how pharmacists' practice has expanded.

**ACPE #0129-0000-17-023-L01-P**

**The Pharmacology and Toxicology of the "Holy Trinity"**

*Jon E. Sprague, R.Ph., PhD, Director & BCI Eminent Scholar  
The Ohio Attorney General's Center for the Future of Forensic Science  
Bowling Green State University*

At the completion of this activity, the participant will be able to:

1. discuss the different pharmacological mechanisms of opioids, benzodiazepines and the skeletal muscle relaxant, carisoprodol;
2. identify the sign and symptoms associated with the toxicity of the "Holy Trinity"; and
3. discuss the cellular mechanisms that result in potentiation of the "high" and respiratory depression of the three agents.

**ACPE #0129-0000-17-024-L04-P**

**Ohio Research Forum 2017**

*Moderator: Timothy R. Ulbrich, PharmD, Associate Dean, Workforce Development and Practice Advancement, NEOMED*

At the completion of this activity, the participant will be able to:

1. identify research projects being conducted by pharmacists, student pharmacists and faculty in Ohio; and

2. describe the impact these research projects have on the practice of pharmacy, economic/social/administrative areas within the profession and/or the design of pharmacy education.

**ACPE #0129-0000-17-025-L01-P**

**Medical Care of the Transgender Patient**

*Maria Barnett, DO, Clinical Assistant Professor and Andrew Keaster, MD, Internal Medicine PGY-3; OSU Wexner Medical Center Department of Family Medicine*

At the completion of this activity, the participant will be able to:

1. explain the DSM criteria and definition of gender dysphoria;
2. distinguish the differences between gender identity, gender expression, natal sex, and sexual orientation and describe the term transgender;
3. recognize barriers and health inequities faced by individuals who are transgender/ gender nonconforming;
4. describe an approach to transgender patients in a culturally competent manner;
5. identify criteria used to determine if a patient is a candidate for hormone therapy;
6. discuss medications used and suggested monitoring parameters when prescribing hormone therapy for transgender patients; and
7. identify and access resources to assist transgender patients with social and health related needs.

**ACPE #0129-0000-17-026-L01-P**

**Pain Management in the Orthopedic Population: Outpatient and Inpatient Considerations**

*Joseph Horsfall, PharmD, MBA, BCGP, Director of Pharmacy  
Crystal Clinic Orthopaedic Center*

At the completion of this activity, the participant will be able to:

1. discuss the CDC Opioid Prescribing Guidelines;
2. review the Ohio Guidelines for Prescribing Opioids for the Treatment of Chronic, Non-Terminal Pain and the Ohio Guideline for the Management of Acute Pain Outside of Emergency Departments from the Governor's Cabinet Opiate Action Team;
3. describe the role quality metrics have in reimbursement for inpatient orthopedic surgical procedures and identify ways to discuss these meaningfully with leadership staff to promote pharmacy involvement in performance improvement strategies;
4. identify key components of multimodal analgesic therapy; and
5. recommend pharmacologic treatment for pain management for orthopedic patients in both the inpatient and outpatient settings.

**ACPE #0129-0000-17-027-L04-P**

**Ohio Innovative Practice Forum 2017**

*Jennifer Rodis, PharmD, BCPS, Assistant Dean for Outreach and Engagement, OSU College of Pharmacy;  
Timothy R. Ulbrich, PharmD, Associate Dean, Workforce Development and Practice Advancement, NEOMED*

At the completion of this activity, the participant will be able to:

1. describe innovative pharmacy practice models in Ohio;
2. identify how individual pharmacy practices and practitioners are expanding patient care services;
3. describe the successes and challenges of these programs including their financial viability and impact on outcome measures; and
4. apply these ideas, opportunities, and resources to enhance his/her own pharmacy practice.

**ACPE #0129-0000-17-028-L01-P**

**3, 2, 1...Deprescribe!**

*Albert Barber, PharmD, CGP, Consulting Pharmacist, CRx Consulting; and  
Stacey Rexrode, PharmD, BCGP, Palliative Care Clinical Pharmacist, Optum*

At the completion of this activity, the participant will be able to:

1. explain the tripartite approach to deprescribing;
2. list three enablers and three barriers to deprescribing;
3. identify three target medication classes for deprescribing in palliative and geriatric populations; and
4. describe how to properly discontinue medications of select medication classes.

**ACPE #0129-0000-17-029-L04-P**

**Through the Looking Glass: Leading Throughout Your Career**

*Brigid Groves, R.Ph., PharmD, MS, Clinical Coordinator, Kroger; Jeff Steckman, R.Ph., PharmD, Pharmacy Sales Manager, Kroger; Marialice Bennett, R.Ph., FAPhA, Faculty Emeritus, OSU College of Pharmacy*

At the completion of this activity, the participant will be able to:

1. describe the pathways to leadership from a variety of perspectives;
2. discuss methods by which one can lead from where they stand; and
3. compare and contrast the concept of Big L vs. little l leaders.

**ACPE #0129-0000-17-030-L03-P**

**State of Ohio Board of Pharmacy Law Update, Spring 2017**

*Steven W. Schierholt, Esq., Executive Director; Sheri Zapadka, R.Ph., Compliance Specialist; State of Ohio Board of Pharmacy*

At the completion of this activity, the participant will be able to:

1. identify recent changes in state and federal laws and rules which impact pharmacy practice;
2. describe the effect of recent changes in laws and rules on his/her specific practice of pharmacy; and
3. review commonly asked questions about existing pharmacy laws and rules.

**ACPE #0129-0000-17-031-L04-P**

**Functional Medicine: A Primer for Pharmacists**

*Lauren N. Anderson, R.Ph., PharmD, Pharmacy Manager, Walmart Pharmacy*

At the completion of this activity, the participant will be able to:

1. define Functional Medicine (FM);
2. list the six core principles of FM;
3. compare and contrast conventional medicine, integrative medicine and FM;
4. describe the seven underlying clinical imbalances;
5. utilize FM tools in a case study, including the Timeline, the Matrix and GO-TO-IT; and
6. describe proposed roles for pharmacists in FM.

**ACPE #0129-0000-17-032-L04-P**

**Emerging Payment Opportunities for Pharmacists: An Overview of Value-Based Payments**

*Stuart J. Beatty, PharmD, BCACP, CDE, Vice Chair of Clinical Affairs  
Associate Professor of Clinical Pharmacy, OSU College of Pharmacy*

At the completion of this activity, the participant will be able to:

1. discuss basic knowledge on billing techniques available;
2. describe the impact of Ohio CPC and CPC+ on primary care payment reform in Ohio; and
3. recognize how to leverage value-based payments to initiate or expand pharmacy services.

**ACPE #0129-0000-17-033-L04-P**

**Creating a Chronic Care Management Program in a Clinical Setting**

*Lauren Miller, R.Ph., PharmD, Pharmacy Preceptor and Nathan Luce, R.Ph., PharmD, PGY-1 Pharmacy Resident, The Centers for Families and Children*

At the completion of this activity, the participant will be able to:

1. define chronic care management (CCM);
2. recognize the importance of chronic care management;
3. discuss a pharmacist led service plan;
3. examine chronic care management implementation;
4. describe the CCM process in the clinical setting; and
5. identify pitfalls in completing CCM.

**ACPE #0129-0000-17-034-L04-P**

**Effective and Respectful Engagement of Individuals with Mental Illness**

*Patrick Runnels, MD, Medical Director and Ryan Bender, R.Ph., PharmD, Pharmacy Manager, The Centers for Families and Children*

At the completion of this activity, the participant will be able to:

1. define Patient-centered, Recovery-oriented care and apply these concepts to interactions with individuals with mental illness;
2. describe how Motivational Interviewing can and should be applied to improve engagement and participation in clinical care; and
3. define Trauma-informed Care and consider how trauma impacts an individual's ability to engage.

**ACPE #0129-0000-17-035-L04-P**

**Managing Your #1 Asset, Your Pharmacy Staff**

*Mark BonDurant, R.Ph., COO/Owner Clark's Rx, Chief Consultant for Independent Rx Consulting*

At the completion of this activity, the participant will be able to:

1. describe knowledge and skills needed to be a better manager;
2. discuss ideas on how to direct and motivate your staff; and
3. recognize ways to have a positive culture in his/her business.

**ACPE #0129-0000-17-036-L01-P**

**Probiotics: Hoax or Health Tool?**

*Cortney Mospan, BCACP, CGP, Assistant Professor of Pharmacy, Wingate University School of Pharmacy, Wingate, NC*

At the completion of this activity, the participant will be able to:

1. differentiate prebiotic, probiotic, and synbiotic and therapeutic benefit they may confer;
2. demonstrate an understanding of patient populations and conditions in which prebiotics, probiotics, and synbiotics have demonstrated therapeutic benefit;
3. list key information to provide during patient counseling, such as storage, appropriate administration, and contraindications for use; and
4. apply clinical evidence discussed to patient cases in order to make appropriate recommendations surrounding probiotic use

**ACPE #0129-0000-17-037-L04-P**

**Managing and Empowering the Next Generation of Pharmacists**

*Ashley Coleman, PharmD, Pharmacy Director and Katie Forte, CPhT, Training and Operations Manager, Medication Management Program, OSU College of Pharmacy*

At the completion of this activity, the participant will be able to:

1. describe ways to empower students to take on clinical roles while providing them with structure to maintain clinical quality;
2. categorize various student personalities and appropriate management styles; and
3. evaluate how to coach students on various patient communication barriers, clinical skills, and professional development.

**ACPE #0129-0000-17-038-L04-P**

**Innovative Pharmacy Business Plan Competition 2017**

*Finalist teams and panel of judges TBA*

At the completion of this activity, the participant will be able to:

1. identify essential components of a business plan, including mission statement, description of business, loan request, marketing plan and financial reports;
2. explain the importance of effective visual aids and nonverbal communication during presentation of a business plan; and
3. recognize how enthusiasm, professionalism and completeness can impact the effectiveness of a business plan presentation.

**ACPE #0129-0000-17-039-L01-P**

**A Primer on Schizophrenia and its Treatment**

*Patrick Runnels, MD, Medical Director and Ryan Bender, R.Ph., PharmD, Pharmacy Manager, The Centers for Families and Children*

At the completion of this activity, the participant will be able to:

1. describe the most current theory on the pathophysiology of schizophrenia;
2. define the criteria for diagnosing schizophrenia, including the following terms: positive and negative symptoms, disorganization, hallucinations and delusions; and
3. describe common conceptual approaches to pharmacology and best practices around engaging patients in medication treatment.

**ACPE #0129-0000-17-040-L01-P**

**Maximize Your Veterinary Treatment Options**

*Chris Simmons, VP Creative Development, PCCA*

At the completion of this activity, the participant will be able to:

1. discuss through case studies how unique dosage forms have been used in a variety of species;
2. discuss innovative ways to solve medication compliance;
3. recognize unique dosage forms available to meet the needs issues; and
4. explain laws governing veterinarians prescribing of compounds.

**ACPE #0129-0000-17-041-L05-P**

**Stick It To 'Em: Insulin Safety, Errors, and Prevention Strategies**

*Liz Hess, PharmD, MS, FISMP*

*Medication Safety Coordinator, St. Vincent Indianapolis*

At the completion of this activity, the participant will be able to:

1. identify available insulin and associated medical supplies on the market;
2. discuss inpatient and outpatient insulin errors;
3. recognize risks in transitions of care;
4. outline error-reduction strategies for insulin; and
5. identify resources for medication safety.

**ACPE #0129-0000-17-042-L01-P**

**Alzheimer's and Dementia: Remembering the Importance of Non-Pharmacologic Therapies**

*Kristen Finley Sobota, PharmD, BCPS, CGP and Kelly Reilly Kroustos, PharmD, CGP, CDP*

*Associate Professors of Pharmacy Practice, ONU Raabe College of Pharmacy*

At the completion of this activity, the participant will be able to:

1. review symptoms related to Alzheimer's and dementia including Behaviors and Psychological Symptoms of Dementia (BPSD);
2. evaluate current literature in support of non-pharmacologic therapies for patients with Alzheimer's and dementia-related behaviors such as BPSD;
3. describe the role of the pharmacist as the medication expert in impacting patients and caregivers with Alzheimer's and dementia;
4. explore ways to organize, design, and utilize fidget blankets in various practice settings; and
5. promote to patients, caregivers, and healthcare providers the importance of music therapy to optimize quality of life and outcomes.

**ACPE #0129-0000-17-043-L04-P**

**Management of DIR Fees and Payer's Perspectives on Managing Specialty Pharmaceuticals**

*Valerie Fortin, Sr. Director, PBM Relations*

*McKesson, AccessHealth*

At the completion of this activity, the participant will be able to:

1. explain the history of Direct and Indirect Remuneration (DIR) fees;
2. review methods to prepare for DIRs fees;
3. discuss how performance impacts reimbursement;
4. list options to improve pharmacy performance;
5. recognize that "specialty" can be a very broad definition;

6. review various specialty dispensing locations;
7. discuss perspective on the PBM/Plan Sponsor relationship as it relates to network design and industry trends; and
8. recognize the link between cost containment and PBM/Plan Sponsor specialty strategies.

**ACPE #0129-0000-17-044-L01-P**

**Updates in Community-Based Antimicrobial Stewardship, HIV, Clostridium difficile, and Antibiotic Durations**

*Lauren Lopez, PharmD, BCPS, Antimicrobial Stewardship Team Lead; Brittany Trimble, PharmD, Clinical Pharmacist; and David M. Robinson, PharmD, BCPS, Clinical Pharmacist  
OhioHealth Grant Medical Center, Columbus*

At the completion of this activity, the participant will be able to:

1. review new developments in HIV pharmacotherapy;
2. recognize the latest recommendations for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP);
3. review established and emerging treatment strategies for *Clostridium difficile* infections;
4. identify strategies for reducing *Clostridium difficile* infections in transitions of care;
5. explain the benefits of shorter courses of antibiotic therapy;
6. recognize the appropriate duration of antibiotic therapy for select bacterial infections (i.e. bronchitis, UTI, sinusitis, otitis media, cellulitis, CAP);
7. identify which populations or bacterial infections are NOT appropriate for shorter courses of antibiotic therapy;
8. discuss the importance of antimicrobial stewardship in the community; and
9. review the latest guidelines and policy documents related to community-based antimicrobial stewardship.

**ACPE #0129-0000-17-045-L01-P**

**New Drug Update 2017**

*Karen L. Kier, PhD, M.Sc., R.Ph., Director of Assessment and Professor of Clinical Pharmacy Practice, Ohio Northern University College of Pharmacy*

At the completion of this activity, the participant will be able to:

1. describe the pharmacology and therapeutics of the drugs presented that were released to market within the past year;
2. state the indications and clinical applications of the medications presented;
3. identify the most common adverse effects, toxicities, and significant drug-drug interactions reported with these medications; and
4. explain important patient counseling information on these medications.

**ACPE #0129-0000-17-046-L04-P**

**Legislative Update 2017**

*Ernest Boyd, PharmD (Hon), CAE, and Antonio Ciaccia, OPA Lobbyists*

At the completion of this activity, the participant will be able to:

1. explain recently approved legislation that requires technician registration and certification for certain activities, and the new requirements for opiate prescriptions;
2. recognize the impact of updates to the PBM law in Ohio;
3. discuss recent legislation that allows pharmacists to substitute biosimilar drugs; and
4. describe the expansion of access resulting from passage of HB 332 which allows pharmacists to inject certain long-acting medications.

**ACPE #0129-0000-17-047-L04-P**

**Ethics in Pharmacy Practice: Case Study Debates**

*Dennis M. Sullivan, MD, MA (Ethics), Director, Center for Bioethics  
Professor of Pharmacy Practice; and PharmD Candidates Christian Carroll, Jeremy Flikkem, Neal Fox and Tyler Michael, Cedarville University*

At the completion of this activity, the participant will be able to:

1. describe the state and federal regulations related to participation in these ethically controversial practices;
2. recognize the competing ethical duties that influence pharmacist decision-making in these ethically controversial practices; and
3. describe the legal costs of participating in or declining to participate in these ethically controversial practices.

**ACPE #0129-0000-17-048-L04-P**

**Creation and Implementation of a Clinical Pharmacy Consult Agreement: Challenges and Successes along the Way**

*Beth Powell, R.Ph., PharmD, Clinical Pharmacist/Residency Preceptor and David Meyer, R.Ph., PharmD, Clinical Pharmacist/Residency Preceptor; The Centers for Families and Children, Cleveland*

At the completion of this activity, the participant will be able to:

1. review the recent changes in Ohio law and Board of Pharmacy rules affecting consult agreements;
2. explain how to create a customized consult agreement;
3. discuss the impact of consult agreements on patient care; and
4. recognize the significance of creating a clinical pharmacy consult agreement at your practice site.

**ACPE #0129-0000-17-049-L01-P**

***Biosimilars***

*Evan Wright, R.Ph., PharmD, Clinical Pharmacist/Residency Preceptor, The Centers for Families and Children, Cleveland*

At the completion of this activity, the participant will be able to:

1. define biosimilar products and differentiate between biological products;
2. explain the development and approval process basics for biosimilar products as well as state regulations for dispensing;
3. define interchangeability and the related rules regarding pharmacy-level substitution;
4. review costs of current biologics and the effects of biosimilars on cost savings; and
5. discuss challenges associated with approval of biosimilars.

**ACPE #0129-0000-17-050-L04-P**

**Implementing Pharmacogenomic Testing in Community Pharmacy**

*Sue Paul, R.Ph., SyneRxgy Consulting, LLC; Alex Lin, Ph.D., Assistant Professor; Jonathan Penm, Ph.D.; and Keith Dolby, PharmD Candidate; University of Cincinnati, College of Pharmacy*

At the completion of this activity, the participant will be able to:

1. describe the importance of pharmacogenomics testing in today's market;
2. identify key stakeholders that provide pharmacogenomics testing;
3. identify the potential market and practice models for offering pharmacogenomics testing;
4. describe the unique challenges faced in community pharmacy for offering pharmacogenomics testing; and
5. describe the financial impact of offering pharmacogenomics testing in the community pharmacy setting.

**ACPE #0129-0000-17-051-L05-P**

**Avoiding Medication Errors Associated with Vaccinations**

*Donald Bennett, R.Ph., MBA, Clinical Assistant Professor, The Ohio State University*

At the completion of this activity, the participant will be able to:

1. identify medication errors commonly associated with vaccinations;
2. discuss the ramifications of medication errors with vaccinations and possible corrective actions;
3. discuss work place policy and procedures and strategies that can help minimize the risk of errors; and
4. describe the process to submit errors to the Institute for Safe Medication Practices (ISMP) National Vaccine Errors Reporting Program (VERP).